CL2009000022A1 - Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. - Google Patents

Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.

Info

Publication number
CL2009000022A1
CL2009000022A1 CL2009000022A CL2009000022A CL2009000022A1 CL 2009000022 A1 CL2009000022 A1 CL 2009000022A1 CL 2009000022 A CL2009000022 A CL 2009000022A CL 2009000022 A CL2009000022 A CL 2009000022A CL 2009000022 A1 CL2009000022 A1 CL 2009000022A1
Authority
CL
Chile
Prior art keywords
von willebrand
factor
willebrand factor
procedure
human
Prior art date
Application number
CL2009000022A
Other languages
English (en)
Inventor
Ristol Debart Pere
Mercedes Faro Tomas Maria
Ignacio Jorquera Nieto Juan
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39316136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of CL2009000022A1 publication Critical patent/CL2009000022A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/022—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

EL PROCEDIMIENTO SE CARACTERIZA POR LA PREPARACIÓN DE UNA SOLUCIÓN DE FACTOR VON WILLEBRAND O DE COMPLEJO DE FACTOR VIII/ FACTOR VON WILLEBRAND QUE CONTIENE FVW A UNA CONCENTRACIÓN DE HASTA 12 UI FVWRC0/M1 Y UNA PROPORCIÓN ENTRE FACTOR VON WILLEBRAND/FACTOR VIII SUPERIOR O IGUAL A 0,4; Y PROCEDER A CONTINUACIÓN A LA NANOFILTRACIÓN DE LA SOLUCIÓN PREPARADA EN A) MEDIANTE UN FILTRO DE TAMAFIO DE PORO MENOR DE 35 NANÓMETROS.
CL2009000022A 2008-01-08 2009-01-07 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. CL2009000022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200800021A ES2298096B1 (es) 2008-01-08 2008-01-08 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.

Publications (1)

Publication Number Publication Date
CL2009000022A1 true CL2009000022A1 (es) 2009-11-20

Family

ID=39316136

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000022A CL2009000022A1 (es) 2008-01-08 2009-01-07 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.

Country Status (16)

Country Link
US (2) US8354505B2 (es)
EP (1) EP2078730B9 (es)
JP (1) JP4976366B2 (es)
CN (1) CN101480490B (es)
AR (1) AR072441A1 (es)
AT (1) ATE509031T1 (es)
AU (1) AU2008255137C1 (es)
BR (1) BRPI0900057B8 (es)
CA (1) CA2645701C (es)
CL (1) CL2009000022A1 (es)
ES (2) ES2298096B1 (es)
MX (1) MX2008015892A (es)
NZ (1) NZ573400A (es)
PL (1) PL2078730T3 (es)
PT (1) PT2078730E (es)
RU (1) RU2417096C2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
ES2682249T3 (es) * 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
US9359397B2 (en) 2011-06-24 2016-06-07 Asahi Kasei Medical Co., Ltd. Method for manufacturing protein drug
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
AU2014346343B2 (en) * 2013-11-08 2018-05-10 Csl Ltd. New method to concentrate von Willebrand factor or complexes thereof
EP3152230B1 (en) * 2014-06-06 2019-08-07 Octapharma AG Preparation comprising factor viii and von willebrand factor peptides
CN104804078B (zh) * 2015-05-05 2019-01-04 广东卫伦生物制药有限公司 人体血清凝血因子ⅷ中的病毒过滤方法
EP3642225A1 (en) 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
KR20200038309A (ko) 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
US20240342254A1 (en) 2021-08-11 2024-10-17 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
RU2256464C1 (ru) * 2004-03-12 2005-07-20 Общество с ограниченной ответственностью "БиоГениус" Способ получения с1-эстеразного ингибитора человека и продукт для использования в медицине
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu

Also Published As

Publication number Publication date
AR072441A1 (es) 2010-09-01
AU2008255137C1 (en) 2015-08-27
AU2008255137A1 (en) 2009-07-23
JP4976366B2 (ja) 2012-07-18
ATE509031T1 (de) 2011-05-15
MX2008015892A (es) 2009-07-07
ES2298096A1 (es) 2008-05-01
RU2008151957A (ru) 2010-07-10
EP2078730B1 (en) 2011-05-11
EP2078730A1 (en) 2009-07-15
CA2645701A1 (en) 2009-07-08
BRPI0900057B8 (pt) 2021-06-29
PT2078730E (pt) 2011-07-14
HK1129075A1 (zh) 2009-11-20
CN101480490A (zh) 2009-07-15
EP2078730B9 (en) 2011-12-21
NZ573400A (en) 2010-02-26
US8354505B2 (en) 2013-01-15
JP2009161528A (ja) 2009-07-23
CN101480490B (zh) 2013-05-29
PL2078730T3 (pl) 2011-10-31
BRPI0900057B1 (pt) 2021-03-23
ES2363827T3 (es) 2011-08-17
US20090176709A1 (en) 2009-07-09
RU2417096C2 (ru) 2011-04-27
AU2008255137B2 (en) 2011-04-07
US20110275570A1 (en) 2011-11-10
CA2645701C (en) 2013-09-17
ES2298096B1 (es) 2009-01-01
BRPI0900057A2 (pt) 2009-09-22

Similar Documents

Publication Publication Date Title
CL2009000022A1 (es) Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.
CO6450630A2 (es) Preparacion de solucion que contiene anticuerpos en una alta concentracion
AR086465A1 (es) Un articulo higienico para uso personal de un hombre
PH12012501274A1 (en) Oral care compositions for use with an oral light device
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
ES2687651T3 (es) Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
TR201809514T4 (tr) Uzun süre etkili insülin formülasyonları.
AR084770A1 (es) Absorcion de oxigeno y dioxido de carbono en un recipiente de un solo uso con un soporte absorbente debajo del filtro
CO7081142A2 (es) Métodos de tratamiento de enfermedades de degeneración retiniana
ES2530624T3 (es) Composiciones de adhesivo
MX2016002492A (es) Composiciones bioactivas derivables de concentrados de plaquetas, y metodos para prepararlas y usarlas.
PE20120169A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
EA201201623A1 (ru) Лечение диабета 2 типа
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
PE20151085A1 (es) Composicion de xantofilas
JP2010138139A5 (es)
AR067352A1 (es) Preparado de fruta estable con elevada concentracion de goma de acacia
AR085998A1 (es) Aclidinio y su uso en la mejora de la calidad del sueño
PL391056A1 (pl) Kompozycja w postaci płynu do pielęgnacji soczewek kontaktowych i materiałów medycznych
AR093605A1 (es) Composicion liquida de limpieza para superficies duras
AR105995A1 (es) Composición de líquido de fracturación y modo de utilización
UY31575A1 (es) "procedimiento para la obtención de un concentrado de factor von willebrand o del complejo factor viii/factor von willebrand y aplicaciones"